索凡替尼治疗中国局部晚期或转移性分化型甲状腺癌和甲状腺髓样癌患者:一项多中心、开放标签、II期试验
这项在中国10个中心开展的II期开放标签Simon两阶段研究纳入59例局部晚期或转移性分化型甲状腺癌(DTC1组26例、DTC2组6例)或甲状腺髓样癌(MTC组27例)患者,每日口服索凡替尼300 mg,28天为一周期。总体客观缓解率为23.2%(95%CI 12.98-36.42),疾病控制率87.5%(95%CI 75.93-94.82),总体中位无进展生存期11.1个月(95%CI 5.98-16.69)。
要点
- 总体客观缓解率23.2%,DTC1组21.7%、DTC2组33.3%、MTC组22.2%。
- 总体疾病控制率87.5%,DTC1组87.0%、DTC2组83.3%、MTC组88.9%。
- ≥3级治疗中出现的不良事件最常见为高血压(20.3%)和蛋白尿(11.9%)。
核心结论
- 索凡替尼对局部晚期或转移性MTC、RAI难治性DTC或无法接受RAI的局部晚期不可切除复发患者显示出有前景的疗效,安全性可耐受且可控。
研究设计与样本
- II期开放标签Simon两阶段设计研究,在中国10个中心开展。
- 共纳入59例患者:DTC1组26例(RAI难治性DTC伴局部晚期或远处转移)、DTC2组6例(初始手术有限后出现局部晚期不可切除复发且因残留正常甲状腺组织不考虑RAI治疗)、MTC组27例(局部晚期或远处转移)。
- 患者每日口服索凡替尼300 mg,28天为一周期。
- 主要终点为研究者评估的客观缓解率。
主要发现
- 总体客观缓解率为23.2%(95%CI 12.98-36.42):DTC1组21.7%、DTC2组33.3%、MTC组22.2%。
- 49例患者达到疾病控制,总体疾病控制率87.5%(95%CI 75.93-94.82):DTC1组87.0%、DTC2组83.3%、MTC组88.9%。
- 中位起效时间总体为59.0天,DTC1组59.0天、DTC2组85.5天、MTC组59.0天。
- 总体中位无进展生存期为11.1个月(95%CI 5.98-16.69);DTC1组和MTC组均为11.1个月,DTC2组在数据截止时未达到中位值。
- 最常见的≥3级治疗中出现的不良事件为高血压(20.3%)、蛋白尿(11.9%),血压升高、高甘油三酯血症和肺部炎症各占5.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid cancer is the most common endocrine tumor with an increasing incidence. Limited treatment options are available for patients with advanced or recurrent metastatic disease, resulting in a poor prognosis. Surufatinib targets multiple kinases (vascular endothelial growth factor receptors, fibroblast growth factor receptor-1, and colony-stimulating factor-1 receptor) involved in tumor angiogenesis and tumor immune evasion. Surufatinib has demonstrated promising antitumor activity in various advanced solid tumors. This study aimed to determine the objective response rate (ORR) of surufatinib in patients with locally advanced or distant metastatic differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC). Methods: This Phase II open-label study by Simon's two-stage design was conducted at 10 sites across China. Patients with radioiodine (RAI)-refractory DTC with locally advanced disease or distant metastasis (DTC1 group); patients who received limited initial surgery and then developed locally advanced unresectable recurrences and were not considered candidates for RAI therapy due to residual normal thyroid tissue (DTC2 group); or patients with MTC with locally advanced disease or distant metastasis (MTC group) were enrolled. A total of 59 patients were enrolled (26 in DTC1, 6 in DTC2, and 27 in MTC) and received 300 mg surufatinib daily in 28-day cycles. The primary endpoint was ORR as determined by the investigators. Results: Overall ORR was 23.2% [95% confidence interval, CI 12.98-36.42]: 21.7% in the DTC1 cohort, 33.3% in the DTC2 cohort, and 22.2% in the MTC cohort. Forty-nine patients achieved disease control (87.5% [CI 75.93-94.82]): 87.0% in the DTC1 cohort, 83.3% in the DTC2 cohort, and 88.9% in the MTC cohort. Median time to response was 59.0 days, and 59.0, 85.5, and 59.0 days in the DTC1, DTC2, and MTC cohorts. Overall median progression-free survival was 11.1 months [CI 5.98-16.69]; 11.1 months in DTC1 and MTC cohorts, while the DTC2 cohort had not reached the median at the data cutoff. The most common treatment-emergent adverse events grade ≥3 were hypertension (20.3%), proteinuria (11.9%), and then elevated blood pressure, hypertriglyceridemia, and pulmonary inflammation (5.1% each). Conclusions: Surufatinib demonstrated promising efficacy with a tolerable and manageable safety profile for patients with locally advanced or metastatic MTC, RAI-refractory DTC, or locally advanced unresectable recurrences unable to receive RAI.
引用
- Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial. Thyroid. 2020. PMID: 32075524. doi:10.1089/thy.2019.0453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。